evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 1 reviews · Urology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 50%Low 3 · 50%Moderate 0 · 0%High 0 · 0%

Gemcitabine vs BCG

Adverse events grade 3 to 5 Range of · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy

It is very uncertain whether gemcitabine changes grade III–V adverse events compared with BCG (very low certainty).

1 finding from 1 review

Gemcitabine vs BCG

Adverse events: grade 1 to 2 · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy

It is very uncertain whether gemcitabine changes grade I or II adverse events compared with BCG (very low certainty).

1 finding from 1 review

Gemcitabine vs mitomycin

Grade I or II adverse events (local adverse events which did not result in delay intravesical treatment) · patients with non‐muscle invasive bladder cancer

Gemcitabine may leads to lower grade I or II adverse events (local adverse events which did not… compared with mitomycin (low certainty).

1 finding from 1 review

Gemcitabine vs mitomycin

Grade III–V adverse events (local adverse events which result in delay intravesical treatment were regarded as Grade III–V complications) · patients with non‐muscle invasive bladder cancer

It is very uncertain whether gemcitabine changes grade III–V adverse events (local adverse events which result in… compared with mitomycin (very low certainty).

1 finding from 1 review